Home > Insider Trading > Filing (0001415889-24-018162)

Filing Details

Accession Number:: 0001415889-24-018162
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-06-25 17:45:38
Reporting Period:: 2024-06-20

Accepted Time:: 2024-06-25 17:45:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1811063	Nuvation Bio Inc.	NUVB	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1487815	Xiangmin Cui	C/O Nuvation Bio Inc. 1500 Broadway, Suite 1401 New York NY 10036		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2024-06-20	87,715	$2.99	1,762,951	No	4	P	Indirect	By Decheng Capital Global Healthcare Fund (Master), LP
Class A Common Stock	Acquisiton	2024-06-21	75,411	$3.00	1,838,362	No	4	P	Indirect	By Decheng Capital Global Healthcare Fund (Master), LP
Class A Common Stock	Acquisiton	2024-06-24	336,874	$2.98	2,175,236	No	4	P	Indirect	By Decheng Capital Global Healthcare Fund (Master), LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Decheng Capital Global Healthcare Fund (Master), LP
No	4	P	Indirect	By Decheng Capital Global Healthcare Fund (Master), LP
No	4	P	Indirect	By Decheng Capital Global Healthcare Fund (Master), LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	314,106	Indirect	By Decheng Capital China Life Sciences USD Fund III, L.P.
Class A Common Stock	4,183,002	Indirect	By Decheng Anbio Limited

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.93 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
These securities are owned directly by Decheng Anbio Limited ("SPV"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.